Copyright
©The Author(s) 2024.
World J Transplant. Sep 18, 2024; 14(3): 94914
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.94914
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.94914
Table 4 Univariate and multivariate analysis for the composite endpoint of hepatocellular carcinoma recurrence or all-cause mortality
Univariate analysis | P value | Multivariate analysis | P value | |
Variables | ||||
Sex | 1.94 (95%CI: 0.79-4.76) | 0.15 | 2.02 (95%CI: 0.82-4.96) | 0.12 |
Age at LT | 1.03 (95%CI: 1.00-1.06) | 0.10 | 1.02 (95%CI: 0.98-1.05) | 0.33 |
Aetiology of liver disease | ||||
HBV | 1.33 (95%CI: 0.72-2.44) | 0.37 | ||
HCV | 1.21 (95%CI: 0.70-2.10) | 0.50 | ||
NAFLD | 0.97 (95%CI: 0.39-2.41) | 0.95 | ||
Statin use | 1.20 (95%CI: 0.59-2.41) | 0.62 | 1.16 (95%CI: 0.58-2.30) | 0.67 |
Aspirin use | 1.01 (95%CI: 0.22-4.61) | 0.99 | 1.21 (95%CI: 0.28-5.27) | 0.80 |
Metformin use | 0.68 (95%CI: 0.31-1.50) | 0.34 | 0.61 (95%CI: 0.27-1.36) | 0.23 |
Statins, aspirin or metformin use1 | 1.10 (95%CI: 0.60-2.01) | 0.76 | 1.06 (95%CI: 0.56-1.91) | 0.85 |
MTORi use | 1.14 (95%CI: 0.59-2.21) | 0.70 | 0.81 (95%CI: 0.43-1.53) | 0.51 |
Pre LT co-morbidities | ||||
Diabetes | 1.08 (95%CI: 0.61-1.93) | 0.79 | ||
Stroke | 0.98 (95%CI: 0.14-7.02) | 0.99 | ||
Hypertension | 0.68 (95%CI: 0.35-1.33) | 0.26 | ||
Obesity | 0.68 (95%CI: 0.37-1.26) | 0.22 | ||
Ischaemic heart disease | 2.08 (95%CI: 0.52-8.22) | 0.27 | ||
Total cholesterol mmol/L | 0.58 (95%CI: 0.30-1.12) | 0.11 | ||
Other variables | ||||
Microvascular invasion | 3.54 (95%CI: 1.97-6.34) | < 0.01 | 2.82 (95%CI: 1.51-5.27) | < 0.01 |
Pre-LT AFP ≥ 100 ng/mL pre-LT | 3.04 (95%CI: 1.53-6.02) | < 0.01 | 2.73 (95%CI: 1.38-5.40) | < 0.01 |
Pre-LT Regional treatments ≥ 3 | 1.26 (95%CI: 0.73-2.18) | 0.41 | ||
Pre-LT size of largest lesion ≥ 3 cm | 1.62 (95%CI: 0.93-2.83) | 0.092 | 1.50 (95%CI: 0.86-2.61) | 0.16 |
Beyond Milan | 2.06 (95%CI: 1.19-3.56) | 0.01 | ||
Beyond up-to-7 | 2.25 (95%CI: 1.23-4.10) | < 0.01 | 1.68 (95%CI: 0.94-2.99) | 0.077 |
Complete response at LT | 0.77 (95%CI: 0.43-1.38) | 0.38 |
- Citation: Chung W, Wong K, Ravindranayagam N, Tang L, Grace J, Wong D, Con D, Sinclair M, Majumdar A, Kutaiba N, Hui S, Gow P, Muralidharan V, Dobrovic A, Testro A. Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study. World J Transplant 2024; 14(3): 94914
- URL: https://www.wjgnet.com/2220-3230/full/v14/i3/94914.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i3.94914